Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 8/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | S100A4 | P26447 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861252 | 0.83 | PIN1 (0.38) | MAPTPIN1 | |
| SCHEMBL3867090 | 0.81 | PTGES (0.43) | PTGESEGFRFBP1LMNASMN1; SMN2 | |
| SCHEMBL3870002 | 0.76 | PTGES (0.40) | PTGESEGFRMAPT | |
| SCHEMBL25361030 | 0.75 | PIN1 (0.31) | MAPTPIN1 | |
| SCHEMBL26620010 | 0.75 | PTGES (0.49) | PTGESEGFRFBP1LMNAMAPT | |
| SCHEMBL31424455 | 0.75 | PTGES (0.51) | PTGESEGFRFBP1LMNAMAPT | |
| SCHEMBL3862005 | 0.74 | PTGES (0.41) | PTGESEGFRFBP1LMNAHPGD | |
| SCHEMBL6760464 | 0.74 | PTGES (0.43) | PTGESEGFRFBP1MAPT | |
| SCHEMBL4157332 | 0.73 | PDE10A (0.40) | LMNASMN1; SMN2MAPT | |
| SCHEMBL202476 | 0.72 | PTGES (0.49) | PTGESEGFRFBP1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598382-B2 | Aryl substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7091214-B2 | Aryl substituted Imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-25 | — | — | US | disclosed |
| EP-1590348-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004058759-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | PTGES 296/4885EGFR 3216/4885FBP1 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.